Progressive liver impairment as a predictor of reduced survival in individuals with EGFR-mutated non-small cell lung cancer and liver metastases undergoing treatment with EGFR tyrosine kinase inhibitors

1

Liver metastasis in advanced non-small cell lung cancer is linked to poor prognosis and reduced efficacy of EGFR tyrosine kinase inhibitors.
2

Consecutive Liver Function Abnormality (CLFA) is proposed as a dynamic biomarker for risk stratification in patients with liver metastases undergoing EGFR-TKI treatment.
3

The study evaluated the prognostic significance of CLFA in patients with EGFR-mutant NSCLC and liver metastases receiving first-line EGFR-TKIs.
4

Persistent liver function abnormalities during treatment may indicate ongoing hepatic injury and affect drug metabolism.
5

The study's findings could enhance understanding of liver function's role in treatment outcomes for patients with EGFR-mutant NSCLC and liver metastases.

Bmc Cancer

by Wen Zhang, Xuemei Wu, Xiaorong Sun, Jian Wen, Xiaoli He, Mingzhou Zhang, Guansong Wang, Zhi Xu
January 23, 2026

1